We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Abbott Announces Results of Early Tenders and Consents in Exchange Offers and Execution of Supplemental Indenture PR Newswire ABBOTT PARK, Ill., March 7, 2017 ABBOTT PARK, Ill., March 7, 2017...
IDEXX Laboratories Set to Join the S&P 500; Chemours to Join S&P MidCap 400; Shake Shack to Join S&P SmallCap 600 PR Newswire NEW YORK, Jan. 3, 2017 NEW YORK, Jan. 3, 2017...
Mit dem System ist bei der Katheterablation eine präzisere Abbildung der Herzanatomie möglich; die Behandlung von Patienten mit Herzrhythmusstörungen kann damit optimiert werden Das...
Le système permet une cartographie cardiaque plus rapide et plus précise lors de l'ablation par cathéter, ce qui optimise le traitement des patients souffrant d'arythmie cardiaque St...
System enables faster, more accurate heart mapping during catheter ablation to optimize treatment for patients with cardiac arrhythmias St. Jude Medical, Inc. (NYSE:STJ), a global...
Board of Directors declare fourth quarter dividend of $0.31 per share, subject to merger closing St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that...
Le nouvel étiquetage assure que les patients qui ont besoin de futures IRM peuvent disposer d’un accès complet au système de SME non rechargeable Proclaim Elite et à la technologie innovante...
New labeling ensures patients in need of future MRIs can have full access to the recharge-free Proclaim Elite SCS System and the company’s innovative BurstDR stimulation technology St...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data...
New labeling ensures patients in need of future full-body MRIs can have access to the recharge-free Proclaim Elite SCS System and the company’s proprietary BurstDR stimulation technology...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions